Patient and transplant characteristics
| Parameter . | D-CMV–/R-CMV– (n = 4287) . | D-CMV+/R-CMV– (n = 1703) . | D-CMV–/R-CMV+ (n = 3630) . | D-CMV+/R-CMV+ (n = 7008) . |
|---|---|---|---|---|
| Underlying malignancy* | ||||
| ALL | 1454 (34%) | 597 (35%) | 1119 (31%) | 1988 (28%) |
| AML | 2833 (66%) | 1106 (65%) | 2511 (69%) | 5020 (72%) |
| Male sex (recipient)* | 2451 (57%) | 1052 (62%) | 1846 (51%) | 3732 (53%) |
| Recipient’s age, y* | 39 (18-76) | 41 (18-75) | 43 (18-76) | 43 (18-77) |
| Male sex (donor)* | 2782 (65%) | 941 (55%) | 2420 (67%) | 3939 (56%) |
| Donor/recipient sex matching* | ||||
| Female to male | 767 (18%) | 443 (26%) | 560 (15%) | 1491 (21%) |
| White blood count at diagnosis, × 109/L† | 14.3 (0.1-879) | 13.3 (0.1-850) | 14.6 (0.2-800) | 14.1 (0.1-790) |
| Donor type*‡ | ||||
| HLA-identical sibling or syngeneic | 2090 (49%) | 856 (50%) | 1403 (39%) | 4504 (64%) |
| Other | 2197 (51%) | 847 (50%) | 2227 (61%) | 2504 (36%) |
| Conditioning* | ||||
| MAC | 3320 (77%) | 1274 (75%) | 2621 (72%) | 5244 (75%) |
| RIC | 967 (23%) | 429 (25%) | 1009 (28%) | 1764 (25%) |
| Cytogenetic risk group§ | ||||
| Good | 183 (9%) | 76 (9%) | 163 (9%) | 328 (10%) |
| Intermediate | 1136 (53%) | 455 (51%) | 941 (54%) | 1847 (56%) |
| Poor | 807 (38%) | 365 (41%) | 653 (37%) | 1149 (35%) |
| Remission status at allo-SCT§ | ||||
| 1. CR | 2704 (63%) | 1064 (63%) | 2132 (59%) | 4309 (62%) |
| 2. CR | 831 (19%) | 320 (19%) | 728 (20%) | 1367 (20%) |
| Active disease | 752 (18%) | 319 (19%) | 770 (21%) | 1332 (19%) |
| Stem cell source* | ||||
| BM | 1307 (31%) | 501 (29%) | 990 (27%) | 1656 (24%) |
| PB | 2980 (70%) | 1202 (71%) | 2640 (73%) | 5352 (76%) |
| TCD* | ||||
| No | 2265 (53%) | 910 (53%) | 1725 (48%) | 4214 (60%) |
| ATG | 1138 (27%) | 451 (27%) | 1263 (35%) | 1663 (24%) |
| Alemtuzumab | 499 (12%) | 177 (10%) | 380 (11%) | 491 (7%) |
| Ex vivo | 385 (9%) | 165 (10%) | 262 (7%) | 640 (9%) |
| Number of transplants per center* | 104 (1-339) | 105 (1-339) | 101 (1-339) | 90 (1-339) |
| Year of allo-SCT* | May 2006 (1998-2009) | February 2006 (1998-2009) | October 2006 (1998-2009) | Sept. 2006 (1998-2009) |
| Follow-up, mo§ | 26 (0.1-157) | 27 (0.1-156) | 24 (0.6-153) | 24 (0.5-154) |
| Parameter . | D-CMV–/R-CMV– (n = 4287) . | D-CMV+/R-CMV– (n = 1703) . | D-CMV–/R-CMV+ (n = 3630) . | D-CMV+/R-CMV+ (n = 7008) . |
|---|---|---|---|---|
| Underlying malignancy* | ||||
| ALL | 1454 (34%) | 597 (35%) | 1119 (31%) | 1988 (28%) |
| AML | 2833 (66%) | 1106 (65%) | 2511 (69%) | 5020 (72%) |
| Male sex (recipient)* | 2451 (57%) | 1052 (62%) | 1846 (51%) | 3732 (53%) |
| Recipient’s age, y* | 39 (18-76) | 41 (18-75) | 43 (18-76) | 43 (18-77) |
| Male sex (donor)* | 2782 (65%) | 941 (55%) | 2420 (67%) | 3939 (56%) |
| Donor/recipient sex matching* | ||||
| Female to male | 767 (18%) | 443 (26%) | 560 (15%) | 1491 (21%) |
| White blood count at diagnosis, × 109/L† | 14.3 (0.1-879) | 13.3 (0.1-850) | 14.6 (0.2-800) | 14.1 (0.1-790) |
| Donor type*‡ | ||||
| HLA-identical sibling or syngeneic | 2090 (49%) | 856 (50%) | 1403 (39%) | 4504 (64%) |
| Other | 2197 (51%) | 847 (50%) | 2227 (61%) | 2504 (36%) |
| Conditioning* | ||||
| MAC | 3320 (77%) | 1274 (75%) | 2621 (72%) | 5244 (75%) |
| RIC | 967 (23%) | 429 (25%) | 1009 (28%) | 1764 (25%) |
| Cytogenetic risk group§ | ||||
| Good | 183 (9%) | 76 (9%) | 163 (9%) | 328 (10%) |
| Intermediate | 1136 (53%) | 455 (51%) | 941 (54%) | 1847 (56%) |
| Poor | 807 (38%) | 365 (41%) | 653 (37%) | 1149 (35%) |
| Remission status at allo-SCT§ | ||||
| 1. CR | 2704 (63%) | 1064 (63%) | 2132 (59%) | 4309 (62%) |
| 2. CR | 831 (19%) | 320 (19%) | 728 (20%) | 1367 (20%) |
| Active disease | 752 (18%) | 319 (19%) | 770 (21%) | 1332 (19%) |
| Stem cell source* | ||||
| BM | 1307 (31%) | 501 (29%) | 990 (27%) | 1656 (24%) |
| PB | 2980 (70%) | 1202 (71%) | 2640 (73%) | 5352 (76%) |
| TCD* | ||||
| No | 2265 (53%) | 910 (53%) | 1725 (48%) | 4214 (60%) |
| ATG | 1138 (27%) | 451 (27%) | 1263 (35%) | 1663 (24%) |
| Alemtuzumab | 499 (12%) | 177 (10%) | 380 (11%) | 491 (7%) |
| Ex vivo | 385 (9%) | 165 (10%) | 262 (7%) | 640 (9%) |
| Number of transplants per center* | 104 (1-339) | 105 (1-339) | 101 (1-339) | 90 (1-339) |
| Year of allo-SCT* | May 2006 (1998-2009) | February 2006 (1998-2009) | October 2006 (1998-2009) | Sept. 2006 (1998-2009) |
| Follow-up, mo§ | 26 (0.1-157) | 27 (0.1-156) | 24 (0.6-153) | 24 (0.5-154) |
Shown are numbers of patients (%) or medians (range). Data are not available for missing patients from the total cohort.
ATG, antithymocyte globulin; TCD, T-cell depletion.
P (global) < .0001.
Missing data in 2076, 765, 1939, and 3625 patients, respectively.
Different donor types are shown in detail in supplemental Table 1.
P < .05.